TrialNature medicine2025

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.

Roy S Herbst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.